Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin

  • Authors:
    • Keiichi Kontani
    • Osamu Taguchi
    • Yoshitomo Ozaki
    • Jun Hanaoka
    • Satoru Sawai
    • Shuhei Inoue
    • Hajime Abe
    • Kazuyoshi Hanasawa
    • Shozo Fujino
  • View Affiliations

  • Published online on: October 1, 2003     https://doi.org/10.3892/ijmm.12.4.493
  • Pages: 493-502
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The use of dendritic cells (DCs) for cancer vaccination is effective in suppressing cancer progression. This is because the DCs play a crucial role in priming tumor-specific immunity efficiently as antigen-presenting cells. In this study, we analyzed the ability of DCs to elicit tumor-specific immunity and clinical effects of DC vaccine immunotherapy targeting MUC1 tumor antigens. DCs from 14 patients with advanced or metastatic breast or lung cancer (9 positive for MUC1 and 5 negative for MUC1) were loaded with MUC1 antigens or tumor lysate and used for therapeutic vaccination. After vaccination, all the MUC1-positive patients acquired antigen-specific immunity whereas only 1 case with MUC1-negative cancer showed the specific immunity. Clinically, marked effects such as reduction in tumor sizes or tumor marker levels or disappearance of malignant pleural effusion were observed in 7 of the 9 MUC1-positive cases. However, MUC1-negative patients did not respond to DC vaccines, with the exception of 1 case with MAGE3-positive lung cancer. Survival of MUC1-positive patients was significantly prolonged in comparison with MUC1-negative patients (mean survival: 16.75 versus 3.80 months, p=0.0101). These data suggest that MUC1 is sufficiently immunogenic to elicit strong anti-tumor immunity as a tumor antigen and that DC vaccines targeting MUC1 are useful for immunotherapy of cancer.

Related Articles

Journal Cover

October 2003
Volume 12 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kontani K, Taguchi O, Ozaki Y, Hanaoka J, Sawai S, Inoue S, Abe H, Hanasawa K and Fujino S: Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med 12: 493-502, 2003
APA
Kontani, K., Taguchi, O., Ozaki, Y., Hanaoka, J., Sawai, S., Inoue, S. ... Fujino, S. (2003). Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. International Journal of Molecular Medicine, 12, 493-502. https://doi.org/10.3892/ijmm.12.4.493
MLA
Kontani, K., Taguchi, O., Ozaki, Y., Hanaoka, J., Sawai, S., Inoue, S., Abe, H., Hanasawa, K., Fujino, S."Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin". International Journal of Molecular Medicine 12.4 (2003): 493-502.
Chicago
Kontani, K., Taguchi, O., Ozaki, Y., Hanaoka, J., Sawai, S., Inoue, S., Abe, H., Hanasawa, K., Fujino, S."Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin". International Journal of Molecular Medicine 12, no. 4 (2003): 493-502. https://doi.org/10.3892/ijmm.12.4.493